Jazz Pharmaceuticals Gets Second “Approvable” Letter For Once-Daily Luvox
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks further information on chemistry, manufacturing and controls for Luvox CR NDA.
You may also be interested in...
Jazz/Solvay Gain Approval Of Luvox CR
Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.
Jazz/Solvay Gain Approval Of Luvox CR
Approval of anxiety/obsessive compulsive disorder drug comes a day ahead of its scheduled user fee date.
Jazz Pharmaceuticals’ Luvox CR Gets Feb. 29 Action Date
Company expects to launch the extended-release anti-anxiety medication in the first quarter, after FDA accepts response to “approvable” letter.